JPRN-UMIN000027165未知2 期
A study to evaluate the efficacy of Eribulin retreatment in HER2 negative Metastatic Breast Cancer patients - Phase II study - - Evaluation of Eribulin retreatment - Phase II study
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1.Patient with active infection 2.Pregnant, lactating, or intends to become pregnant 3.brain metastasis with clinical symptoms 4.Physician concludes that the patient's participation in this trial is inappropriate
研究者
相似试验
已完成
不适用
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35
已完成
不适用
Evaluation of safety and efficacy of eribulin for patients advanced or recurrent HER2 negative breast cancer who have been treated with anthracyclines and taxanesBreast cancerJPRN-UMIN000007121Kyushu Breast Cancer Study Group50
招募中
不适用
Exploratory clinical study of eribulin followed by taxane for metastatic breast cancer patientsMetastatic breast cancerJPRN-UMIN000027527Yamaguchi University Graduate School of Medicine30
招募中
2 期
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.Advanced/recurrent HER2-positive breast cancerJPRN-UMIN000011020Sairtama Breast Cancer Clinical Study Group (SBCCSG)na35
进行中（未招募）
1 期
A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic canceradvanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2017-003621-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA25